AIM ImmunoTech (AIM) Invested Capital (2018 - 2025)
Historic Invested Capital for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to -$6.1 million.
- ImmunoTech's Invested Capital fell 30868.82% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year decrease of 30868.82%. This contributed to the annual value of -$1.3 million for FY2024, which is 11291.77% down from last year.
- Per ImmunoTech's latest filing, its Invested Capital stood at -$6.1 million for Q3 2025, which was down 30868.82% from -$6.5 million recorded in Q2 2025.
- ImmunoTech's Invested Capital's 5-year high stood at $30.1 million during Q2 2023, with a 5-year trough of -$6.5 million in Q2 2025.
- Its 3-year average for Invested Capital is $5.9 million, with a median of $3.9 million in 2024.
- In the last 5 years, ImmunoTech's Invested Capital crashed by 7975.11% in 2024 and then tumbled by 30868.82% in 2025.
- Over the past 3 years, ImmunoTech's Invested Capital (Quarter) stood at $10.2 million in 2023, then plummeted by 112.92% to -$1.3 million in 2024, then plummeted by 359.68% to -$6.1 million in 2025.
- Its Invested Capital was -$6.1 million in Q3 2025, compared to -$6.5 million in Q2 2025 and -$3.9 million in Q1 2025.